Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Xiaohua Wei, PM
CONTACT
Mingyue Zeng, APM
CONTACT
Lead
Zhuhai Beihai Biotech Co., Ltd
This is a multicenter, open label phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic profile of BH009 in patients with advanced squamous head and neck cancer (non-nasopharyngeal) and ovarian cancer, and to initially explore its clinical effectiveness. This study will use a "3+3" dose escalation design to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of BH009.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted